While there was a positive trend in the monotherapy cohort, there was no statistical improvement in OS.

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk ...

Ahsan Arozullah, MD, MPH, Senior Vice President and Head of Oncology Development, Astellas "Men with nmHSPC with high-risk biochemical recurrence are very likely to experience disease progression.

"The survival benefits of intervention with XTANDI in advanced prostate cancer are well-recognized," added Shontelle Dodson, Executive Vice President, Head of Medical Affairs, Astellas. "The ...

A U.S. FDA panel of independent experts beat back an effort by Pfizer (NYSE:PFE) to expand the patient population for its prostate cancer treatment Talzenna (talazoparib). Members of the Oncologic ...

In a statement, NICE said the new guidance for Talzenna will make it an option for around 2,400 people in England and reduce pressure on the NHS, as current therapies can require clinic visits. The ...

Erleada showed a 23% reduction in mortality compared to Xtandi in real-world settings, offering potential survival benefits for metastatic castration-sensitive prostate cancer patients. Real-world ...